用于治疗难治性抗nmda受体脑炎硼替佐米治疗。
Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
该文综述了硼替佐米治疗多发性骨髓瘤的临床应用进展。
Clinical progress on bortezomib in the treatment for multiple myeloma was reviewed.
研究硼替佐米对黏附介导骨髓瘤细胞的阿霉素耐药逆转作用。
To study the effects of bortezomib on the cell adhesion and the cell adhesion mediated adriamycin resistance of RPMI8226 cells.
单用硼替佐米或联合伊立替康对复发或耐药的结直肠癌无效。
Bortezomib alone or in combination with irinotecan was not effective in patients with relapsed or refractory CRC.
我们研究了硼替佐米单药在骨髓增生异常综合征中应用的有效性和安全性。
We performed a study on efficacy and safety of bortezomib as a single agent in patients with myelodysplastic syndromes (MDS).
目的探讨硼替佐米单独或联合了氧化二砷对HL - 60细胞凋亡的影响。
Objective to investigate the effect of bortezomib alone and in combination with arsenic trioxide on apoptosis of HL-60 cells.
并重点介绍了已上市抗肿瘤药物硼替佐米的药理作用机制、合成方法、药效及临床研究。
The mechanism, synthesis, pharmacodynamics and clinic trial of the launched anti-tumor drug bortezomib were emphatically introduced.
目的观察硼替佐米联合地塞米松治疗复发、难治性多发性骨髓瘤(MM)患者的疗效和不良反应。
Objective to investigate the efficacy and toxicity of bortezomib in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (MM).
目的观察硼替佐米联合地塞米松治疗复发、难治性多发性骨髓瘤(MM)患者的疗效和不良反应。
Objective to investigate the efficacy and toxicity of bortezomib in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (MM).
应用推荐